Clinical trial
Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating…
NCT00049517 · Eastern Cooperative Oncology Group, Other · Completed
Key facts
| NCT number | NCT00049517 |
|---|---|
| Title | Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Patients With AML Leukemia |
| Official title | A Phase III Trial in Adult Acute Myeloid Leukemia: Daunorubicin Dose-Intensification Prior to Risk-Allocated Autologous Stem Cell Transplantation |
| Lead sponsor | Eastern Cooperative Oncology Group, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Leukemia |
| Intervention type | Biological, Drug, Procedure |
| Interventions | sargramostim, busulfan, cyclophosphamide, cytarabine, gemtuzumab ozogamicin (GO), Daunorubicin, Autologous HCT, Allogeneic HCT |
| Enrollment | 657 |
| Start date | Dec 19, 2002 |
| Primary completion | Mar 1, 2009 |
| Completion | Dec 1, 2019 |
| First posted | Jan 27, 2003 |
| Last update posted | Jun 15, 2023 |
| Countries | Israel, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: